SMMT — Summit Therapeutics PLC
NASDAQ · Healthcare · Biotechnology
$14.10
-$0.06 (-0.42%)
Summit Therapeutics PLC (SMMT) is a biotechnology company listed on NASDAQ. It is led by Robert W. Duggan, based in 601 Brickell Key Drive, Miami, FL, United States, 33131, with about 265 employees. Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Net income was -$231.8M. SMMT currently screens at market cap $11.46B.
Use this SMMT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SMMT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SMMT SEC filings page. Lician reads the product cache first so this HTML stays unique to Summit Therapeutics PLC even when a live quote feed is slow.
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
SMMT Key Statistics
Market Cap
$11.46B
Volume
6.25M
Previous Close
$12.73
Day Range
$13.05 – $13.60
EPS
-$0.31
Revenue
$0.00
Net Income
-$221.31M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
265
SMMT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $705.00K | $1.81M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$221.31M | -$614.93M | -$78.78M | -$88.60M |
| EPS (Diluted) | -$0.31 | -$0.99 | -$0.41 | -$0.67 |
Total Assets
$435.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$104.86M
Operating Cash Flow
-$142.11M
Free Cash Flow
$0.00
Summit Therapeutics PLC Company Information
- Co-CEO & Executive Chairman
- Robert W. Duggan
- Headquarters
- 601 Brickell Key Drive, Miami, FL, United States, 33131
- Website
- www.smmttx.com
- Phone
- 305 203 2034
- IPO / Founded
- 2015-03-05
- Sector
- Healthcare
- Industry
- Biotechnology